MAXONA Pharmaceuticals Launches Scientific Advisory Board to Accelerate MAX-001 Development for Pain Management

MAXONA Pharmaceuticals Sets Sights on Pain Management Innovation



MAXONA Pharmaceuticals is taking an important stride in the landscape of pain management with the establishment of its newly formed Scientific Advisory Board (SAB). This board's primary objective is to provide strategic guidance as the company advances the development of MAX-001—their lead compound, an innovative non-opioid and non-NSAID oral therapy aimed at treating both acute and chronic pain.

Held recently in Malvern, Pennsylvania, this first SAB meeting assembled a distinguished group of experts in pain management, signaling a milestone in the clinical development plan for MAX-001. The therapy is centered around a proprietary formulation of nefopam, a analgesic that has been widely used globally but is not currently available in the United States. MAX-001 is believed to offer a unique profile, possibly transforming how pain is managed in healthcare.

Shawn Fatholahi, President and CEO of MAXONA Pharmaceuticals, highlighted the significance of the SAB meeting, stating, “We are extremely pleased with the progress to date in bringing MAX-001 to the U.S. market, marking another key milestone in our development program.”

Chaired by Roy Freeman, MD, an esteemed neurologist at Harvard Medical School, the SAB consists of healthcare professionals specializing in pain management, clinical research, and drug development. Dr. Freeman expressed confidence in the board’s capacity to steer the project amid the ever-evolving field of pain management.

The recent Phase 1 clinical trial results have shown promise for MAX-001, revealing that the therapy has been well tolerated by participants without any serious adverse effects. This positive feedback sets the stage for the anticipated submission of the Investigational New Drug (IND) application, with plans to launch a Phase 2 clinical program later this year.

Todd Bertoch, MD, a principal investigator at CenExel JBR and SAB member, echoed the excitement surrounding the development of new non-opioid treatment options in the U.S. He stated, “It is an exciting time in the field of pain management with innovative efforts underway to bring new non-opioid, non-NSAID oral therapy options to market for patients in the U.S. who suffer from acute and chronic pain.”

Nadine Attal, a professor specializing in Therapeutics and Pain Medicine, also emphasized the benefits of nefopam, which has been successfully used in France for years. She provided insights during the meeting on the drug’s rapid onset of action and potency in pain management and discussed the importance of further research into its pharmacokinetics and safety profile.

As MAXONA Pharmaceuticals navigates this innovative pathway with MAX-001, the board aims to explore a multi-modal approach to pain management, maximizing treatment efficacy through collaborative strategies and other potential combinations of therapies.

The lineup of participants for the inaugural SAB meeting included:
  • - Praveen Anand, MD, from Imperial College London
  • - Paul Desjardins, DMD, PhD, from Rutgers School of Dental Medicine
  • - Robert Dworkin, PhD, University of Rochester
  • - Jessica McCoun, MD, from CenExel Atlanta Center
  • - Jessica Oswald, MD, MPH, from UC San Diego Health
  • - Mark Wallace, MD, from UC San Diego Health Center

With the backing of a robust SAB and encouraging initial trial results, MAXONA Pharmaceuticals is poised to contribute to the pain management landscape in a meaningful way, offering hope for patients seeking non-opioid alternatives for relief.

For more information about MAXONA Pharmaceuticals and its aspirations, visit www.maxonapharm.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.